Med. Pro Praxi 2008; 5(6): 240-244

Kardiovaskulární důsledky diabetes mellitus a jejich prevence

MUDr. Martin Prázdný CSc., Ph.D
III. interní klinika VFN a 1. LF UK, Praha

Diabetes mellitus obou typů je závažný rizikový faktor pro rozvoj cévních komplikací, ať už se jedná o komplikace makrovaskulární nebo mikrovaskulární. Zároveň se stále vzrůstající prevalencí diabetu 2. typu nejen v České republice, ale i v celém světě, se objevují nové léčebné postupy a léky, které mají za cíl ovlivnit pozitivně kompenzaci diabetu a redukovat kardiovaskulární riziko. Jednotlivé skupiny perorálních antidiabetik se od sebe podstatně liší mechanizmem účinku i možností ovlivnění prognózy pacienta. Odlišně působí i různé typy inzulinu. Navíc v diabetologii pro některé situace ve vztahu ke kardiovaskulárním komplikacím postrádáme důkazy založené na validních klinických studiích. Ani odpověď na otázku, zda je přísná metabolická kompenzace diabetu u všech pacientů jednoznačnou cestou ke snížení kardiovaskulárního rizika, není jasná. Kardiovaskulární a cerebrovaskulární onemocnění však stále zůstávají u pacientů s diabetem nejčastější příčinou úmrtí. Stále více se tak v širších souvislostech ukazuje, že u pacientů s diabetem se nelze omezit pouze na léčbu hyperglykémie, ale současně je nutné léčit a ovlivňovat i všechny ostatní ovlivnitelné rizikové faktory.

Keywords: kardiovaskulární riziko, diabetes mellitus, hyperglykémie, arteriální hypertenze

Published: December 19, 2008  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Prázdný M, D P. Kardiovaskulární důsledky diabetes mellitus a jejich prevence. Med. praxi. 2008;5(6):240-244.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Action to Control Cardiovascular Risk in Diabetes (ACCORD). 2006, http://www.accordtrial.org.
    2. Brenner BM, Cooper ME, De Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. New England Journal of Medicine 2001; 345(12): 861-869. Go to original source... Go to PubMed...
    3. Brunkhorst FM, Kuhnt E, Engel C. Intensive insulin therapy in patients with severe sepsis and septic shock is associated with an increased rate of hypoglycemia - Results from a randomized multicenter study (VISEP). Infection 2005; 33 (SUPPL. 1): 19-20.
    4. Cerami A, Vlassara H, Brownlee M. Role of advanced glycosylation products in complications of diabetes. Diabetes Care 1988; 11(SUPPL. 1): 73-79.
    5. Cífková R, Býma S, Češka R, Horký K, Karen I, et al. Prevence kardiovaskulárních onemocnění v dospělém věku. Cor Vasa 2005; 47(9 Suppl.): 3-14.
    6. Česká diabetologická společnost. Standardy péče o diabetes mellitus 2. typu. Diabetologie Metabolismus Endokrinologie Výživa 2007; 10(4): 191-198, www.diab.cz.
    7. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. The Lancet 366(9493): 1279-1289. Go to original source... Go to PubMed...
    8. Feldt-Rasmussen B, Mathiesen ER, Deckert T. Central role for sodium in the pathogenesis of blood pressure changes independent of angiotensin, aldosterone and catecholamines in Type 1 (insulin-dependent) diabetes mellitus. Diabetologia 1987; 30(8): 610-617. Go to original source...
    9. Glucontrol Study: Comparing the Effects of Two Glucose Control Regimens by Insulin in Intensive Care Unit Patients. 2006, http://clinicaltrials.gov/ct/gui/show/NCT00107601.
    10. Hamdy O, Ledbury S, Mullooly C, Jarema C, Porter S, Ovalle K et al. Lifestyle modification improves endothelial function in obese subjects with the insulin resistance syndrome. Diabetes Care 2003; 26(7): 2119-2125. Go to original source... Go to PubMed...
    11. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. The Lancet 1998; 351(9118): 1755-1762. Go to original source... Go to PubMed...
    12. Heart Outcomes Prevention Evaluation (HOPE) Study I. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. The Lancet 2000; 355(9200): 253-259. Go to original source... Go to PubMed...
    13. Heart Protection Study Collaborative Group. Heart Protection Study Collaborative GroupMRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20536 high-risk individuals: a randomised placebo-controlled trial. The Lancet 2002; 360(9326): 23-33. Go to original source... Go to PubMed...
    14. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. The Lancet 2003; 361(9374): 2005-2016. Go to original source... Go to PubMed...
    15. Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham study. Journal of the American Medical Association 1979; 241(19): 2035-2038. Go to original source... Go to PubMed...
    16. Keech AC, Mitchell P, Summanen PA, O'Day J, Davis TME, Moffitt MS, et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. The Lancet 370(9600): 1687-1697. Go to original source... Go to PubMed...
    17. Keech AC. Features of Metabolic Syndrome Identify Individuals with Type 2 Diabetes Mellitus at high risk for CV events and greater benefits of fenofibrate. kongres AHA, Orlando, abstrakt, 2007.
    18. Kligman MD, Dexter DJ, Omer S, Park AE. Shrinking cardiovascular risk through bariatric surgery: application of Framingham risk score in gastric bypass. Surgery 2008; 143(4): 533-538. Go to original source... Go to PubMed...
    19. Malmberg K, Rydén L, Wedel H, Birkeland K, Bootsma A, Dickstein K, et al. FASTTRACK intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): Effects on mortality and morbidity. European Heart Journal 2005; 26(7): 650-661. Go to original source... Go to PubMed...
    20. Malmberg K. Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. British Medical Journal 1997; 314(7093): 1512-1515. Go to original source... Go to PubMed...
    21. McQuigg M, Brown JE, Broom J, Laws RA, Reckless JPD, Noble PA, et al. The Counterweight programme: Prevalence of CVD risk factors by body mass index and the impact of 10 % weight change. Obesity Research and Clinical Practice 2008; 2(1): 15-27. Go to original source... Go to PubMed...
    22. McVeigh GE. Arterial compliance in hypertension and diabetes mellitus. American Journal of Nephrology 1996; 16(3): 217-222. Go to original source... Go to PubMed...
    23. Mesotten D, Swinnen JV, Vanderhoydonc F, Wouters PJ, Van Den Berghe G. Contribution of Circulating Lipids to the Improved Outcome of Critical Illness by Glycemic Control with Intensive Insulin Therapy. Journal of Clinical Endocrinology and Metabolism 2004; 89(1): 219-226. Go to original source... Go to PubMed...
    24. Nathan DM. Sustained Effect of Intensive Treatment of Type 1 Diabetes Mellitus on Development and Progression of Diabetic Nephropathy: The Epidemiology of Diabetes Interventions and Complications (EDIC) Study. Journal of the American Medical Association 2003; 290(16): 2159-2167. Go to original source... Go to PubMed...
    25. National Heart, Lung, and Blood Institute. ACCORD telebriefing prepared remarks. 2008, http://www.nhlbi.nih.gov/health/prof/heart/other/accord/index.htm.
    26. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. New England Journal of Medicine 2007; 356(24): 2457-2471. Go to original source... Go to PubMed...
    27. Parving HH, Lehnert H, chner-Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. New England Journal of Medicine 2001; 345(12): 870-878. Go to original source... Go to PubMed...
    28. Rizzoni D, Porteri E, Guelfi D, Muiesan ML, Valentini U, Cimino A, et al. Structural alterations in subcutaneous small arteries of normotensive and hypertensive patients with non-insulin-dependent diabetes mellitus. Circulation 2001; 103(9): 1238-1244. Go to original source... Go to PubMed...
    29. Rösen P, Nawroth PP, King G, Möller W, Tritschler HJ, Packer L. The role of oxidative stress in the onset and progression of diabetes and its complications: A summary of a congress series sponsored by UNESCO-MCBN, the American diabetes association and the German diabetes society. Diabetes/Metabolism Research and Reviews 2001; 17(3): 189-212. Go to original source... Go to PubMed...
    30. Shamoon H, Duffy H, Fleischer N, Engel S, Saenger P, Strelzyn M, et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. New England Journal of Medicine 1993; 329(14): 977-986. Go to original source... Go to PubMed...
    31. Stratton IM, Adler AI, Neil HAW, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study. British Medical Journal 2000; 321(7258): 405-412. Go to original source... Go to PubMed...
    32. Škrha J, Prázný M, Hilgertová J, Weiserová H. Serum alpha-tocopherol and ascorbic acid concentrations in Type 1 and Type 2 diabetic patients with and without angiopathy. Clinica Chimica Acta 2003; 329(1-2): 103-108. Go to original source... Go to PubMed...
    33. Tesař V. Hypertenze u diabetické nefropatie. In: Anděl M, Klimeš I, Lebl J, Saudek F, eds, Onemocnění ledvin u diabetes mellitus. Praha: Triton 2005; 150-161.
    34. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288(23): 2981-2997. Go to original source... Go to PubMed...
    35. Turner R. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352(9131): 854-865. Go to original source...
    36. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). The Lancet 1998; 352(9131): 837-853. Go to original source... Go to PubMed...
    37. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317(7160): 703-713. Go to original source...
    38. Van Den Berghe G, Wilmer A, Milants I, Wouters PJ, Bouckaert B, Bruyninckx F, et al. Intensive insulin therapy in mixed medical/surgical intensive care units: Benefit versus harm. Diabetes 2006; 55(11): 3151-3159. Go to original source... Go to PubMed...
    39. Vatten LJ, Nilsen TI, Holmen J. Combined effect of blood pressure and physical activity on cardiovascular mortality. Journal of Hypertension 2006; 24(10): 1939-1946. Go to original source... Go to PubMed...
    40. Vaverková H, Soška V, Rosolová H, Češka R, Cífková R, Freiberger T, et al. Doporučení pro diagnostiku a léčbu dyslipidemií v dospělosti, vypracované výborem České společnosti pro aterosklerózu. Cor Vasa 2007; 49(3): K73-K86.
    41. Vlassara H, Brownlee M, Cerami A. Novel macrophage receptor for glucose-modified proteins is distinct from previously described scavenger receptors. Journal of Experimental Medicine 1986; 164(4): 1301-1309. Go to original source... Go to PubMed...
    42. Weidmann P, Ferrari P. Central role of sodium in hypertension in diabetic subjects. Diabetes Care 1991; 14(3): 220-232. Go to original source... Go to PubMed...
    43. Widimský Jr. J, Cífková R, Špinar J, Filipovský J, Grundmann M, Horký K, et al. Doporučení diagnostických a lečebných postupů u arteriální hypertenze - Verze 2007. Cor Vasa 2008; 50(1): K5-K22.
    44. Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. New England Journal of Medicine 2008; 358(15): 1547-1559. Go to original source... Go to PubMed...
    45. Yusuf S. Vitamin E supplementation and cardiovascular events in high-risk patients. New England Journal of Medicine 2000; 342(3): 154-160. Go to original source... Go to PubMed...

    Return to the content


    Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.